These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 15044120)

  • 1. By the way, doctor. I was astounded to read that women who test positive for the breast cancer gene have as much as an 80% risk of getting breast cancer. Shouldn't we all be tested?
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Mar; 11(7):8. PubMed ID: 15044120
    [No Abstract]   [Full Text] [Related]  

  • 2. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can genetic testing guide treatment in breast cancer?
    Tutt A; Ashworth A
    Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
    Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
    Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
    Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
    Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
    Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.
    Lalloo F; Varley J; Moran A; Ellis D; O'dair L; Pharoah P; Antoniou A; Hartley R; Shenton A; Seal S; Bulman B; Howell A; Evans DG
    Eur J Cancer; 2006 May; 42(8):1143-50. PubMed ID: 16644204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France.
    Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C
    Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetrance of BRCA1/BRCA2 specific gene mutations in Iranian women with breast cancer.
    Hashemian AH; Hajizadeh E; Kazemnejad A; Atri M; Mehdipour P
    Saudi Med J; 2009 Jan; 30(1):41-4. PubMed ID: 19139771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
    Kotsopoulos J; Librach CL; Lubinski J; Gronwald J; Kim-Sing C; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Randall S; Manoukian S; Pasini B; Tung N; Ainsworth PJ; Cummings S; Sun P; Narod SA;
    Cancer Causes Control; 2008 Dec; 19(10):1111-9. PubMed ID: 18509731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saskatchewan continues breast cancer screening.
    Lemire EG
    CMAJ; 2002 Apr; 166(8):1012. PubMed ID: 12002972
    [No Abstract]   [Full Text] [Related]  

  • 17. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.
    Kataki A; Gomatos I; Pararas N; Armakolas A; Panousopoulos D; Karantzikos G; Voros D; Zografos G; Markopoulos C; Leandros E; Konstadoulakis M
    Clin Genet; 2005 Apr; 67(4):322-9. PubMed ID: 15733268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
    Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
    Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.
    Engert S; Wappenschmidt B; Betz B; Kast K; Kutsche M; Hellebrand H; Goecke TO; Kiechle M; Niederacher D; Schmutzler RK; Meindl A
    Hum Mutat; 2008 Jul; 29(7):948-58. PubMed ID: 18431737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.